Genomic characteristics and drug screening among organoids derived from non-small cell lung cancer patients.

ABSTRACT:

Background

Patient-derived organoid (PDO) models are highly valuable and have potentially widespread clinical applications. However, limited information is available regarding organoid models of non-small cell lung cancer (NSCLC). This study aimed to characterize the consistency between primary tumors in NSCLC and PDOs and to explore the applications of PDOs as preclinical models to understand and predict treatment response during lung cancer.

Methods

Fresh tumor samples were harvested for organoid culture. Primary tumor samples and PDOs were analyzed via whole-exome sequencing. Paired samples were subjected to immunohistochemical analysis. There were 26 antineoplastic drugs tested in the PDOs. Cell viability was assessed using the Cell Titer Glo assay 7-10 days after drug t

SUBMITTER: Chen JH 

PROVIDER: S-EPMC7396373 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature